Qube Research & Technologies (QRT)
MGX icon

Qube Research & Technologies (QRT)’s Metagenomi Therapeutics MGX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,053
Closed -$4.3K – 4258
2024
Q2 		$4.3K Sell
1,053
-15,614
-94% -$107K ﹤0.01% 3072
2024
Q1 		$176K Buy
+16,667
New +$192K ﹤0.01% 3082

Other funds holding MGX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Qube Research & Technologies (QRT)'s MGX Position: Q3 2024 in Review

Qube Research & Technologies (QRT) sold out of Metagenomi Therapeutics (MGX) in Q3 2024, closing a stake of 1,053 shares — an estimated $4.3K sold.

Qube Research & Technologies (QRT) first reported a position in MGX in Q1 2024 and held it in 2 quarters. The position peaked at $176K in Q1 2024. 67 funds tracked by Wall St. Rank hold MGX as of Q3 2024.

  • Qube Research & Technologies (QRT) reported no remaining Metagenomi Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 1,053 Metagenomi Therapeutics shares in Q3 2024, an estimated $4.3K.
  • Qube Research & Technologies (QRT) first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 2 quarters.
  • Qube Research & Technologies (QRT)'s Metagenomi Therapeutics position peaked at $176K in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2024, filed 14 Nov 2024.